Unifranco Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 28-07-2024
- Paid Up Capital ₹ 0.15 M
as on 28-07-2024
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.80 Cr
as on 28-07-2024
- Revenue -11.78%
(FY 2023)
- Profit 15.09%
(FY 2023)
- Ebitda 24.23%
(FY 2023)
- Net Worth 52.65%
(FY 2023)
- Total Assets 100.24%
(FY 2023)
About Unifranco Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹4.80 Cr.
Narsin Surender and Narsin Akash serve as directors at the Company.
- CIN/LLPIN
U24239AP2006PTC049181
- Company No.
049181
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Feb 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
D, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Unifranco Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narsin Akash  | Director | 05-May-2022 | Current |
| Narsin Surender | Director | 16-Feb-2006 | Current |
Financial Performance of Unifranco Life Sciences.
Unifranco Life Sciences Pvt Ltd, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.78% decrease. The company also saw a substantial improvement in profitability, with a 15.09% increase in profit. The company's net worth Soared by an impressive increase of 52.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unifranco Life Sciences?
In 2023, Unifranco Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Stride Organics Private LimitedActive 19 years 7 monthsNarsin Surender and Narsin Akash are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 23 Mar 2023 | ₹4.80 Cr | Open |
How Many Employees Work at Unifranco Life Sciences?
Unifranco Life Sciences has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unifranco Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unifranco Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
